ArticleScientific reports2026
Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- First case description of a highly aggressive thoracopulmonary primitive neuroectodermal tumor in a Moroccan adult male.Annals of medicine and surgery (2012) · 2026Article
- Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical features, aside from disease stage, have proven insufficient to identify patients at extremely high or low risk. There are few established biological markers for EwS. The discovery of new prognostic and/or predictive biomarkers could improve our understanding of tumor heterogeneity, facilitate individual risk stratification, and aid targeted therapies. We initiated a pan-European study using formalin-fixed, prospectively collected, primary tumors prior to chemotherapy from 335 patients in two clinical trial registries, EURO-Ewing 99 and Ewing 2008, to analyze correlation and survival of ten potential prognostic biomarkers. Immunohistochemical (IHC) analyses were conducted for STEAP1, DKK2, and EZH2, while MIR34A and LGALS3BP expression was investigated by quantitative PCR. Genomic alterations, including gain of chromosome 1q, loss of ADAM3A, loss of chromosome 16q, as well as loss of heterozygosity (LOH) and percentage of the genome altered (PGA), were analyzed by FISH and/or SNP-based arrays of genomic DNA. To consider the observed variation in the number of analyzed samples per biomarker (N = 102–300), effect size measures were computed. Correlations between dichotomized biomarker expressions were generally low, except for those reflecting genomic alterations (ϕ >= 0.20 <= 0.38; P < .05). Several relevant correlations were found with clinical features of the underlying EwS patients (ϕ >= 0.20 <= 0.31; P < .05). Most promising prognostic values with clinically relevant effect sizes (OS), adjusted for known prognostic variables, were high MIR34A expression (HR = 0.29; P < .01), LOH (HR = 2.44; P < .05), and PGA (HR = 2.20; P = .05). This pan-European study identified MIR34A, LOH, and PGA as the most promising biomarkers for the prognosis of survival in a well-characterized EWS patient cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.